Margarida Serra | Head Of Stem Cell Bioengineering Laboratory
iBET: Instituto de Biologia Experimental e Tecnológica

Margarida Serra, Head Of Stem Cell Bioengineering Laboratory, iBET: Instituto de Biologia Experimental e Tecnológica

Margarida Serra is the Head of Stem Cell Bioengineering Laboratory from the Animal Cell Technology Unit of iBET. She is graduated in Biological Engineering at the Instituto Superior Técnico, and holds a PhD in Engineering and Technology Sciences, from NOVA University of Lisbon in 2011. She did part of her PhD studies at the Fraunhofer Institut for Biomedical Engineering, Cellartis AB, and Uniklinik Köln (Germany).The work developed was innovative as for the first time a bioprocess to expand human embryonic stem cells in scalable and fully controlled bioreactors was developed. The key research line is driven by the vision to streamline robust manufacturing of cell therapy products (CTP) with improved functionality, to support phase I/II clinical trials. Her research has focused on the development of novel cell culturing strategies that recreate environmental conditions excelling growth and differentiation/maturation of human pluripotent and adult stem cells, through metabolic and process understanding. Aiming at accelerating CTP translation into the clinic, she has been applying multi-parametric techniques including omics technologies as complementary analytical tools to support bioprocess optimization and CTP potency assessment. Margarida Serra has published over 38 papers, 2 book chapters and supervised 8 PhD students.

Appearances:



Conference Day 2 - Wednesday 1st April 2020 @ 12:20

Bioinspired Manufacturing of hPSC-based Therapy Products

  • Development of novel cell culturing strategies that recreate environmental conditions to excel hPSC proliferation and differentiation/maturation into functional cardiomyocytes and hepatocytes;
  • Advancing manufacture of cell therapy products through metabolic and process understanding
  • Multi-parametric techniques including advanced “-omics” technologies (proteomics, transcriptomics, metabolomics and fluxomics) as complementary analytical tools to support bioprocess understanding and optimization as well as to unveil the mechanism of action of cell therapy products

Conference Day 2 - Wednesday 1st April 2020 @ 16:30

Panel discussion: moving towards ‘smart’ and ‘flexible’ integrated process pipelines

a. What are the common bioprocess units suitable for all ATMP manufacture – technology and scale perspectives? b..…and what are the specialisations when it comes to different therapy types? i.Technologiesii.Tools iii. Data c. Inherently variable field eliminating sources of systemic uncertainty towards process streamliningd. Whole-process intensification in cell therapy manufacturing: room to improve
last published: 04/Jun/20 08:25 GMT

back to speakers